GSK3358699 / GSK - LARVOL DELTA

A Randomized Study of the Safety and Pharmacokinetics of GSK3358699, a Mononuclear Myeloid-Targeted Bromodomain and Extra-Terminal Domain Inhibitor. (PubMed, Br J Clin Pharmacol) - P1 | "Single doses of GSK3358699 are generally well tolerated with significant metabolite concentrations detected in target cells. A complete assessment of pharmacodynamics was limited by assay variability. A causal relationship could not be excluded for cardiac-related AEs, resulting in an inability to identify a suitable repeat-dose regimen and study termination."

Clinical • Journal • PK/PD data • Atrial Fibrillation • Cardiovascular • Immune Modulation • Inflammation • Pain • Ventricular Tachycardia • IL6

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 (clinicaltrials.gov) - P1; N=49; Terminated; Sponsor: GlaxoSmithKline; N=80 ➔ 49; Trial completion date: Sep 2020 ➔ May 2019; Suspended ➔ Terminated; Trial primary completion date: Sep 2020 ➔ May 2019; The trial was terminated for strategic reasons following the emergence of new data.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CRP • F2 • IL6

First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 (clinicaltrials.gov) - P1; N=80; Suspended; Sponsor: GlaxoSmithKline; Trial completion date: Jul 2019 ➔ Sep 2020; Recruiting ➔ Suspended; Trial primary completion date: Jul 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • Trial suspension

Newly added product (GSK Press Release) - P1, Rheumatoid Arthritis

Pipeline update